Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — Market Radius (February 2022)

19 slides from Satellos Bioscience's conference presentation, Feb 9, 2022

  1. Slide 1: Satellos Bioscience Inc. - Rebuilding muscle from within

    Feb 9, 2022 SATELLOS BIOSCIENCE INC. Rebuilding muscle from within TM 1

  2. Slide 2: Legal Disclaimers

    2 Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or perfor

  3. Slide 3: Satellos: Addressing regeneration failure in muscle diseases

    3 Satellos: Addressing regeneration failure in muscle diseases Scientific leaders Muscle is a regenerative organ Massive opportunity Satellite Cell  Identified the muscle stem cells  Muscle is the human body’s giving rise to regeneration largest organ  Discovered dysfunctions which  Diseases spa

  4. Slide 4: Satellos scientific founder: World leader in muscle stem cell research

    4 Satellos scientific founder: World leader in muscle stem cell research Muscle stem cells Muscle loss in Duchenne identified caused by impaired divisions 2000 2009 2013 2016 Dr. Michael Rudnicki Ottawa Hosp. Res. Inst. 2007 2012 2015 2019  Order of Canada  Royal Society Fellow  Canada Res. Chair

  5. Slide 5: Seminal discoveries: Defining muscle stem cell driven cycle of regeneration

    5 Seminal discoveries: Defining muscle stem cell driven cycle of regeneration Muscle stem cell Duchenne muscular dystrophy Impairment Tendon (Pax7+/Myf5-) X Differentiation deficit Dr. Michael Rudnicki Regeneration involves a regulated balance between self-renewal and differentiation Ottawa Hosp. Re

  6. Slide 6: Satellos Strategic Path

    6  Focus initially on rare diseases SATELLOS  Duchene and other dystrophies/atrophies  Massive need, limited options and high value Strategic Path  Potential for accelerated path to market approval  Then broaden to mass market indications  Ageing conditions (e.g., frailty/sarcopenia)  Muscle

  7. Slide 7: Duchenne muscular dystrophy: A failure of muscle regeneration throughout life

    7 Duchenne muscular dystrophy: A failure of muscle regeneration throughout life Current treatments don’t Duchenne patient journey address regeneration Gene correction  ~1 in 3,500 male births  Dystrophin gene mutated Muscle Heart inflammation function Target existing fibers Muscle Energy/ fibrosis

  8. Slide 8: Our solution in Duchenne: Resetting regeneration by correcting stem cell divisions

    8 Our solution in Duchenne: Resetting regeneration by correcting stem cell divisions Satellos Discovery Satellos Solution Satellos Drug Stem cell divisions impaired in Duchenne Correcting stem cell divisions Too many muscle X Not enough muscle Sufficient muscle Sufficient muscle progenitor cells ste

  9. Slide 9: Proof of Concept: Satellos treatment improves outcomes in Duchenne model

    9 Proof of Concept (POC): Satellos treatment improves outcomes in Duchenne model Mdx Q: Can divisions be reset? Mouse Stem cells imbalanced X A: Yes, divisions can be reset Mdx Drug Mouse Stem cells in balance 9

  10. Slide 10: Proof of Concept: Satellos treatment improves outcomes in Duchenne model

    10 Proof of Concept (POC): Satellos treatment improves outcomes in Duchenne model Mdx Enhanced Muscle Quality Q: Can divisions be reset? Mouse  Bigger muscle Stem cells imbalanced  Less fibrosis (green)  Larger fibers (black) X Untreated Treated Diaphragm Enhanced Muscle Performance A: Yes, divis

  11. Slide 11: Confirmation in humans: Some Duchenne boys able to walk well beyond their peers

    Confirmation in humans: Some Duchenne boys able to walk well beyond their peers How is this happening?  A leading Duchenne group at The Ohio State/Nationwide Children’s Hospital1 explored this phenomena  Analyzed 419 boys for factors associated with the continued ability to walk  They identified

  12. Slide 12: Near term priorities to build value in lead program

    12 Near term priorities to build value in lead program 2022 Q1 Q2 Q3 Q4 Output: Multiple candidates suitable for Proof Design / advance drug candidates and file IP of Concept (POC) testing and optimization Evaluate / select lead drug candidates Pre-IND Studies Utility: Precedent in Duchenne for biom

  13. Slide 13: MyoReGenX: Proprietary platform tuned to stem cell divisions

    13 MyoReGenX™: Proprietary platform tuned to stem cell divisions MyoReGenX™ Phenotypic Assay Identified Multiple Pathways/Targets Ex vivo sample In Niche Isolate fibers Self-Renewal Differentiation Wnt7a/Fzd7 EGFR/AurkA Data analysis  siRNAs  Pathways  Drugs  Targets MyoReGenX™ JAK/SAT Undisclos

  14. Slide 14: Medium term value deliverables

    14 Medium term value deliverables: Ph II trials in lead program and 2nd program clinic ready Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Lead Duchenne program in Phase II trials Delivered by Q2/24 Follow-on indication in Phase II trials  Pre-IND studies completed, and Delivered by Q

  15. Slide 15: Value potential is significant: Attractive market capitalizations in muscle space

    15 Value potential is significant: Attractive market capitalizations in muscle space Phase 3 / Commercial 36 – 60 months US$2.7BN US$7.4BN US$0.6BN Phase 1 - 2 Trials 18 – 36 months US$0.2BN US$0.9BN US$0.6BN US$0.9BN Pre-IND/IND 12 – 18 months US$35M Development Stages Timeline Goals PEER COMPANIES

  16. Slide 16: Leadership

    16 Leadership Frank Gleeson, MBA Michael Rudnicki, PhD, OC, FRS Sridhar Narayan, PhD, MBA Geoffrey Mackay Adam Mostafa William Jarosz, JD Board Member and CEO Chief Scientific Officer VP – Drug Discovery Chair — Board of Directors Board Member and Chair – Board Member and CEO – Audit Committee AmpB

  17. Slide 17: Satellos: A Brief History

    17  Co-Founded in 2018 by Frank Gleeson, Dr. Michael Rudnicki and Bloom Burton Development Corp. SATELLOS  Raised US$5M seed funding via HNW investors and Parent Project Muscular Dystrophy (PPMD) A Brief History  Completed reverse merger on TSX in Aug./21 of iCo Therapeutics as financing strategy

  18. Slide 18: Cap Table and Key Professional Providers

    18 SATELLOS (TSX: MSCL.V; OTC: MSCLF) Cap Table and Key Professional Providers KEY PROVIDERS CAPITAL TABLE  Legal: Borden Ladner Gervais, LLP Common Shares 32,995,548  David Henry, LLB, Partner Warrants 2,162,762  Accounting: PricewaterhouseCoopers Stock options 2,847,252  Craig McMillan, CPA, C

  19. Slide 19: Summary

    19  Transformative science in area of broad medical need  Initial focus on rare, lethal disease ‒ Duchenne Summary  Strong founding group and leadership team  Huge potential upside on near term deliverables  Plan for NASDAQ financing in 2022 Satellos Bioscience Inc. 65 Front Street East, Suite

Satellos Bioscience — Market Radius (February 2022) on 6ix